发布时间:
2025
-
07
-
18
On July 18, the Plant-Derived Recombinant Human Albumin Injection, developed by Wuhan Oryzogen Biotechnology Co., Ltd. using "rice-sourced hematopoiesis" technology, was officially approved for marketing for the treatment of hypoalbuminemia (≤30g/L) associated with liver cirrhosis. Upon market launch, this product will become the first human serum albumin injection in China developed using recombinant protein technology.Currently, human serum albumin drugs used in clinical practice are all derived from human plasma through separation and extraction, which carries risks of resource sh...
浏览次数:5